References
1. Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: Atypical features and risks of kasabach-merritt phenomenon in 107 referrals. Journal of Pediatrics . 2013;162(1):142-147. doi:10.1016/j.jpeds.2012.06.044
2. Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt Phenomenon: Classic Presentation and Management Options. Clinical Medicine Insights: Blood Disorders . 2017;10:0-4. doi:10.1177/1179545X17699849
3. Chinello M, Di Carlo D, Olivieri F, et al. Successful management of kaposiform hemangioendothelioma with long-term sirolimus treatment: A case report and review of the literature. Mediterranean Journal of Hematology and Infectious Diseases . 2018;10(1):1-6. doi:10.4084/MJHID.2018.043
4. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have “true” hemangiomas. Journal of Pediatrics . 1997;130(4):631-640. doi:10.1016/S0022-3476(97)70249-X
5. Kasabach H, Merritt K. Capillary Hemangioma With Extensive Purpura.American Journal of Diseases of Children . 1940;59(5):1063-1070. doi:10.1001/archpedi.1940.01990160135009
6. O’Rafferty C, O’Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon.British Journal of Haematology . 2015;171(1):38-51. doi:10.1111/bjh.13557
7. Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform Hemangioendothelioma of Infancy and Childhood. The American Journal of Surgical Pathology . 1993;17(4):321-328. doi:10.1097/00000478-199304000-00001
8. Debelenko L V., Perez-Atayde AR, Mulliken JB, Liang MG, Archibald TH, Kozakewich HPW. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma.Modern Pathology . 2005;18(11):1454-1460. doi:10.1038/modpathol.3800444
9. Seo SK, Suh JC, Na GY, Kim IS, Sohn KR. Kasabach-Merritt syndrome: Identification of platelet trapping in a tufted angioma by immunohistochemistry technique using monoclonal antibody to CD61.Pediatric Dermatology . 1999;16(5):392-394. doi:10.1046/j.1525-1470.1999.00103.x
10. Yao W, Li KL, Qin ZP, et al. Standards of care for Kasabach−Merritt phenomenon in China. World Journal of Pediatrics . 2021;17(2):123-130. doi:10.1007/s12519-020-00379-9
11. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: From discovery to prospects. Journal of Thrombosis and Haemostasis . 2011;9(1):44-55. doi:10.1111/j.1538-7836.2011.04335.x
12. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling.Blood . 2010;116(4):661-670. doi:10.1182/blood-2010-02-270876
13. Gros A, Syvannarath V, Lamrani L, et al. Single platelets seal neutrophil-induced vascular breaches via GPVI during immune-complex-mediated inflammation in mice. Blood . 2015;126(8):1017-1026. doi:10.1182/blood-2014-12-617159
14. Rayes J, Lax S, Wichaiyo S, et al. The podoplanin-CLEC-2 axis inhibits inflammation in sepsis. Nature Communications . 2017;8(1). doi:10.1038/s41467-017-02402-6
15. Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood . 2017;129(14):2013-2020. doi:10.1182/blood-2016-09-742999
16. Inoue O, Hokamura K, Shirai T, et al. Vascular smooth muscle cells stimulate platelets and facilitate thrombus formation through platelet CLEC-2: Implications in atherothrombosis. PLoS ONE . 2015;10(9):1-28. doi:10.1371/journal.pone.0139357
17. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood . 2009;113(12):2835-2842. doi:10.1182/blood-2008-06-159541
18. Phillips WG, Marsden JR. Kasabach-Merritt syndrome exacerbated by platelet transfusion. Journal of the Royal Society of Medicine . 1993;86(4):231-232. doi:10.1177/014107689308600418
19. Drolet BA, Trenor CC, Brandão LR, et al. Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma.Journal of Pediatrics . 2013;163(1):285-291. doi:10.1016/j.jpeds.2013.03.080
20. Koerper MA, Addiego JE, de Lorimier AA, Lipow H, Price D, Lubin BH. Use of aspirin and dipyridamole in children with platelet trapping syndromes. Journal of Pediatrics . 1983;102:311-314.
21. McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. European Heart Journal . 2017;38(47):3488-3492. doi:10.1093/eurheartj/ehx531
22. Thachil J. Antiplatelet therapy – a summary for the general physicians. Clin Med . 2016;16(2):152-160. doi:10.7861/clinmedicine.16-2-152
23. Eble JA, Beermann B, Hinz HJ, Schmidt-Hederich A. α2β1 Integrin Is Not Recognized by Rhodocytin but Is the Specific, High Affinity Target of Rhodocetin, an RGD-independent Disintegrin and Potent Inhibitor of Cell Adhesion to Collagen. Journal of Biological Chemistry . 2001;276(15):12274-12284. doi:10.1074/jbc.M009338200
24. Suzuki-Inoue K. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood . 2006;107(2):542-549. doi:10.1182/blood-2005-05-1994
25. Chang YW, Hsieh PW, Chang YT, et al. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.Oncotarget . 2015;6(40):42733-42748. doi:10.18632/oncotarget.5811
26. Ignatova AA, Ponomarenko EA, Polokhov DM, et al. Flow cytometry for pediatric platelets. Platelets . 2019;30(4):428-437. doi:10.1080/09537104.2018.1513473
27. Martyanov AA, Morozova DS, Sorokina MA, et al. Heterogeneity of integrin αIIbβ3 function in pediatric immune thrombocytopenia revealed by continuous flow cytometry analysis. International Journal of Molecular Sciences . 2020;21(9). doi:10.3390/ijms21093035
28. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. Journal of Biological Chemistry . 1985;260(6):3440-3450. doi:10.1016/s0021-9258(19)83641-4
29. Mindukshev I, Gambaryan S, Kehrer L, et al. Low angle light scattering analysis: A novel quantitative method for functional characterization of human and murine platelet receptors. Clinical Chemistry and Laboratory Medicine . 2012;50(7):1253-1262. doi:10.1515/CCLM.2011.817
30. Greinacher A, Pecci A, Kunishima S, et al. Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders. Journal of Thrombosis and Haemostasis . 2017;15(7):1511-1521. doi:10.1111/jth.13729
31. Morozova DS, Martyanov AA, Korobkina JJD, et al. Granulocytes role in thrombus formation under low shear rate flow conditions as procoagulant platelet scavengers. Published online 2020.
32. Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leukemia and Lymphoma . 2015;56(12):3418-3425. doi:10.3109/10428194.2015.1041385
33. Mack JM, Verkamp B, Richter GT, Nicholas R, Stewart K, Crary SE. Effect of sirolimus on coagulopathy of slow-flow vascular malformations.Pediatr Blood Cancer . 2019;66(10):e27896. doi:10.1002/pbc.27896
34. Martyanov AA, Balabin FA, Dunster JL, Panteleev MA, Gibbins JM, Sveshnikova AN. Control of Platelet CLEC-2-Mediated Activation by Receptor Clustering and Tyrosine Kinase Signaling. Biophysical Journal . Published online April 2020:S0006349520303465. doi:10.1016/j.bpj.2020.04.023
35. Sveshnikova A. Hubs and Webs in Platelet Intracellular Signalling.SBPR . 2021;1(3):31-32. doi:10.52455/sbpr.01.202103014
36. Sveshnikova A, Stepanyan M, Panteleev M, Sveshnikova A, Stepanyan M, Panteleev M. Platelet functional responses and signalling: the molecular relationship. Part 1: responses. Systems Biology and Physiology Reports . 2021;1(1):20. doi:10.52455/sbpr.01.202101014
37. Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi’s sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Modern Pathology . 2000;13(2):180-185. doi:10.1038/modpathol.3880033